Akinchan Bhardwaj։ OCEANIC-STROKE Trial Signals a New Era in Secondary Stroke Prevention
Akinchan Bhardwaj, Consultant Interventional Cardiologist at Kauvery Hospital, shared a post on LinkedIn:
”A new antithrombotic strategy may finally reduce recurrent ischemic stroke without increasing bleeding
At the American Stroke Association International Stroke Conference 2026, the OCEANIC-STROKE trial presented an important signal in secondary stroke prevention.
Asundexian, a Factor XIa inhibitor, when added to standard antiplatelet therapy, reduced recurrent ischemic stroke without increasing major bleeding.
Key takeaways from this late-breaking abstract:
- ~26% relative reduction in recurrent ischemic stroke
- Reduction in disabling stroke
- No increase in intracranial or major bleeding
- Consistent benefit across age, sex, and stroke subtype
- Favorable composite cardiovascular outcomes
Why this matters:
For decades, efforts to intensify antithrombotic therapy after non-cardioembolic ischemic stroke have been constrained by bleeding risk. FXIa inhibition targets thrombosis biology more selectively, potentially separating efficacy from hemorrhage: “a long-standing unmet need”in stroke prevention.
Important context:
• Phase III, >12,000 patients, global trial
• Non-cardioembolic ischemic stroke / high-risk TIA
• Results are preliminary (conference abstract, not yet peer-reviewed)
If confirmed, FXI inhibition may represent a meaningful shift in how we think about long-term secondary stroke prevention.
Looking forward to the full manuscript and imaging substudy data.”
Stay updated with Hemostasis Today.
-
Mar 24, 2026, 17:12Ron DePinho: CRISPR Progress in Cellular Immunotherapy
-
Mar 24, 2026, 17:12Martine Gilard։ Women’s Heart Health as a National Priority
-
Mar 24, 2026, 17:11Erik Nelson։ Blood Vessels – The Silent System That Determines How You Age
-
Mar 24, 2026, 17:10Anthony Yazbeck: Why the Hemolysin Test Matters More Than You Think
-
Mar 24, 2026, 17:09Marcos Gamboa Chele: Are We Asking for Too Many Thrombophilia Panels?
-
Mar 24, 2026, 17:06Anita Brikman: PPTA Explores India’s Growing Plasma-Derived Medicines Industry
-
Mar 24, 2026, 17:01Victor Canata: Is Embolectomy the Best Treatment for Pulmonary Thromboembolism?
-
Mar 24, 2026, 16:57Hossam Qassem: The Stepwise Investigation Framework for ICU Hemoglobin Drop
-
Mar 24, 2026, 16:56Alan Nurden: Targeting Splice Site Variants in Alport Syndrome with Antisense Therapy